Katie S Murray1, Behfar Ehdaie2, John Musser3, Joseph Mashni4, Govindarajan Srimathveeravalli5, Jeremy C Durack6, Stephen B Solomon7, Jonathan A Coleman8. 1. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. 3. Department of Surgery, Tripler Army Medical Center, Honolulu, Hawaii. 4. Department of Surgical Oncology, Banner MD Anderson Cancer Center, Gilbert, Arizona. 5. Radiochemistry and Imaging Sciences Service, Department of Radiology and Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. 6. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. 7. Interventional Radiology Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. 8. Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: colemanj@mskcc.org.
Abstract
PURPOSE: Partial prostate gland ablation is a strategy to manage localized prostate cancer. Irreversible electroporation can ablate localized soft tissues. We describe 30 and 90-day complications and intermediate term functional outcomes in men undergoing prostate gland ablation using irreversible electroporation. MATERIALS AND METHODS: We reviewed the charts of 25 patients with prostate cancer who underwent prostate gland ablation using irreversible electroporation as a primary procedure and who were followed for at least 6 months. RESULTS: Median followup was 10.9 months. Grade 3 complications occurred in 2 patients including epididymitis (1) and urinary tract infection (1). Fourteen patients experienced grade 2 or lower complications, mainly transient urinary symptoms, hematuria and urinary tract infections. Of 25 patients 4 (16%) had cancer in the zone of ablation on routine followup biopsy at 6 months. Of those with normal urinary function at baseline 88% and 94% reported normal urinary function at 6 and 12 months after prostate gland ablation, respectively. By 12 months only 1 patient with normal erectile function at baseline reported new difficulty with potency and only 2 patients (8%) required a pad for urinary incontinence. CONCLUSIONS: Prostate gland ablation with irreversible electroporation is feasible and safe in selected men with localized prostate cancer. Intermediate term urinary and erectile function outcomes appear reasonable. Irreversible electroporation is effective in the ablation of tumor bearing prostate tissue as a majority of men had no evidence of residual cancer on biopsy 6 months after prostate gland ablation.
PURPOSE: Partial prostate gland ablation is a strategy to manage localized prostate cancer. Irreversible electroporation can ablate localized soft tissues. We describe 30 and 90-day complications and intermediate term functional outcomes in men undergoing prostate gland ablation using irreversible electroporation. MATERIALS AND METHODS: We reviewed the charts of 25 patients with prostate cancer who underwent prostate gland ablation using irreversible electroporation as a primary procedure and who were followed for at least 6 months. RESULTS: Median followup was 10.9 months. Grade 3 complications occurred in 2 patients including epididymitis (1) and urinary tract infection (1). Fourteen patients experienced grade 2 or lower complications, mainly transient urinary symptoms, hematuria and urinary tract infections. Of 25 patients 4 (16%) had cancer in the zone of ablation on routine followup biopsy at 6 months. Of those with normal urinary function at baseline 88% and 94% reported normal urinary function at 6 and 12 months after prostate gland ablation, respectively. By 12 months only 1 patient with normal erectile function at baseline reported new difficulty with potency and only 2 patients (8%) required a pad for urinary incontinence. CONCLUSIONS: Prostate gland ablation with irreversible electroporation is feasible and safe in selected men with localized prostate cancer. Intermediate term urinary and erectile function outcomes appear reasonable. Irreversible electroporation is effective in the ablation of tumor bearing prostate tissue as a majority of men had no evidence of residual cancer on biopsy 6 months after prostate gland ablation.
Authors: Duke Bahn; Andre Luis de Castro Abreu; Inderbir S Gill; Andrew J Hung; Paul Silverman; Mitchell E Gross; Gary Lieskovsky; Osamu Ukimura Journal: Eur Urol Date: 2012-03-21 Impact factor: 20.096
Authors: Justin K Lee; Melissa Assel; Alan E Thong; Daniel D Sjoberg; John P Mulhall; Jaspreet Sandhu; Andrew J Vickers; Behfar Ehdaie Journal: Eur Urol Date: 2015-08-17 Impact factor: 20.096
Authors: Robert E Neal; Jeremy L Millar; Helen Kavnoudias; Peter Royce; Franklin Rosenfeldt; Alan Pham; Ryan Smith; Rafael V Davalos; Kenneth R Thomson Journal: Prostate Date: 2014-01-17 Impact factor: 4.104
Authors: Willemien van den Bos; Berrend G Muller; Hashim Ahmed; Chris H Bangma; Eric Barret; Sebastien Crouzet; Scott E Eggener; Inderbir S Gill; Steven Joniau; Gyoergy Kovacs; Sascha Pahernik; Jean J de la Rosette; Olivier Rouvière; Georg Salomon; John F Ward; Peter T Scardino Journal: Eur Urol Date: 2014-01-13 Impact factor: 20.096
Authors: Matthijs J Scheltema; John I Chang; Willemien van den Bos; Ilan Gielchinsky; Tuan V Nguyen; Theo de M Reijke; Amila R Siriwardana; Maret Böhm; Jean J de la Rosette; Phillip D Stricker Journal: Diagn Interv Radiol Date: 2018-09 Impact factor: 2.630
Authors: David Bonekamp; M B Wolf; M C Roethke; S Pahernik; B A Hadaschik; G Hatiboglu; T H Kuru; I V Popeneciu; J L Chin; M Billia; J Relle; J Hafron; K R Nandalur; R M Staruch; M Burtnyk; M Hohenfellner; H-P Schlemmer Journal: Eur Radiol Date: 2018-06-25 Impact factor: 5.315
Authors: Govindarajan Srimathveeravalli; Francois Cornelis; Thomas Wimmer; Sebastien Monette; Simon Y Kimm; Majid Maybody; Stephen B Solomon; Jonathan A Coleman; Jeremy C Durack Journal: J Vasc Interv Radiol Date: 2017-03-30 Impact factor: 3.464
Authors: Matthijs J Scheltema; Arnoud W Postema; Daniel M de Bruin; Mara Buijs; Marc R Engelbrecht; M Pilar Laguna; Hessel Wijkstra; Theo M de Reijke; Jean J M C H de la Rosette Journal: Diagn Interv Radiol Date: 2017 Sep-Oct Impact factor: 2.630
Authors: Jonathan B Bloom; Samuel A Gold; Graham R Hale; Kareem N Rayn; Vikram K Sabarwal; Ivane Bakhutashvili; Vladimir Valera; Baris Turkbey; Peter A Pinto; Bradford J Wood Journal: Gland Surg Date: 2018-04
Authors: Fabian Tollens; Niklas Westhoff; Jost von Hardenberg; Sven Clausen; Michael Ehmann; Frank G Zöllner; Anne Adlung; Dominik F Bauer; Stefan O Schoenberg; Dominik Nörenberg Journal: Radiologe Date: 2021-07-12 Impact factor: 0.635